BLAINJECTIONINJECTABLE
Approved
Mar 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ZARXIO (filgrastim-sndz) by Novartis. Approved for leukocyte growth factor [epc]. First approved in 2015.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZARXIO (filgrastim-sndz) is a biosimilar granulocyte-colony stimulating factor (G-CSF) indicated for leukocyte growth support in patients with cancer receiving chemotherapy, those undergoing bone marrow transplantation, and those with certain blood disorders. It is a recombinant cytokine that stimulates the production and release of neutrophils from bone marrow.
$47MPart D
PeakStable
At peak lifecycle with $47M in Part D spending; stable commercial base supports mid-sized team focused on market defense against biosimilar entrants.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZARXIO positions you in a mature, stable biosimilar franchise within Novartis oncology and hematology. Career opportunities center on regulatory defense, payer engagement, and global market management rather than novel drug development, with emphasis on ethics/compliance and senior scientific leadership.
Executive DirectorRussia Country Ethics
Worked on ZARXIO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.